• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D filed by Heartbeam Inc.

    10/25/23 4:01:55 PM ET
    $BEAT
    Medical/Dental Instruments
    Health Care
    Get the next $BEAT alert in real time by email
    SC 13D 1 d554769dsc13d.htm SC 13D SC 13D

     

     

    UNITED STATES

    SECURITIES & EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    (Amendment No.  )*

     

     

    HEARTBEAM, INC.

    (Name of Issuer)

    Common Stock

    (Title of Class of Securities)

    42238H108

    (CUSIP Number)

    Strome Group, LLC

    Attn: Mark E. Strome

    13535 Ventura Boulevard, Suite C-525

    Sherman Oaks, CA 91423

    (310) 850-9700

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    May 1, 2023

    (Date of Event Which Requires Filing of This Statement)

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☒

     

     

    NOTE: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See § 13d-7(b) for other parties to whom copies are to be sent.

     

     

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     


    CUSIP No.: 42238H108

     

     1.   

     NAME OF REPORTING PERSON

     

     Mark E. Strome

     2.  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     (a) ☐  (b) ☐

     

     3.  

     SEC USE ONLY

     

     4.  

     SOURCE OF FUNDS (SEE INSTRUCTIONS)

     

     OO

     5.  

     CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

     

     ☐

     6.  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     United States of America

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

        7.   

     SOLE VOTING POWER

     

     0

        8.  

     SHARED VOTING POWER

     

     3,150,000 (1)

        9.  

     SOLE DISPOSITIVE POWER

     

     0

       10.  

     SHARED DISPOSITIVE POWER

     

     3,150,000 (1)

    11.   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     3,150,000 (1)

    12.  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    13.  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

     12.0% (2)

    14.  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     IN, HC

     

    (1)

    Mark E. Strome’s beneficial ownership of the Common Stock is comprised of 3,150,000 shares of Common Stock, which are directly owned by Strome Mezzanine Fund II, LP (the “Fund”), Mark E. Strome Living Trust and Strome Dynasty, LLC. Mr. Strome has the authority, directly or indirectly, to vote and dispose of the reported securities held by each of these entities. Mr. Strome disclaims beneficial ownership of the reported securities, except to the extent of his pecuniary interest therein. This report shall not be deemed an admission that Mr. Strome is a beneficial owner of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

    (2)

    Percent of class calculated based on 26,311,904 shares of Common Stock outstanding as of August 9, 2023, as reported by the Issuer in the Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2023 filed with the SEC on August 10, 2023 (the “Form 10-Q”).


    CUSIP No.: 42238H108

     

     1.   

     NAME OF REPORTING PERSON

     

     Strome Investment Management, L.P.

     2.  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     (a) ☐  (b) ☐

     

     3.  

     SEC USE ONLY

     

     4.  

     SOURCE OF FUNDS (SEE INSTRUCTIONS)

     

     OO

     5.  

     CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

     

     ☐

     6.  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

        7.   

     SOLE VOTING POWER

     

     0

        8.  

     SHARED VOTING POWER

     

     2,900,000 (1)

        9.  

     SOLE DISPOSITIVE POWER

     

     0

       10.  

     SHARED DISPOSITIVE POWER

     

     2,900,000 (1)

    11.   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     2,900,000 (1)

    12.  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    13.  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

     11.0% (2)

    14.  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     PN, IA

     

    (1)

    Strome Investment Management, L.P.’s beneficial ownership of the Common Stock is comprised of 2,900,000 shares of Common Stock, which are directly owned by the Fund. As general partner and investment manager of the Fund, Strome Investment Management, L.P. (the “Manager”) has the authority to vote and dispose of the reported securities held by the Fund. The Manager disclaims beneficial ownership of the reported securities, except to the extent of its pecuniary interest therein. This report shall not be deemed an admission that the Manager is a beneficial owner of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

    (3)

    Percent of class calculated based on 26,311,904 shares of Common Stock outstanding as of August 9, 2023, as reported by the Issuer in the Form 10-Q .

     

    - 3 -


    CUSIP No.: 42238H108

     

     1.   

     NAME OF REPORTING PERSON

     

     Strome Mezzanine Fund II, LP

     2.  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     (a) ☐  (b) ☐

     

     3.  

     SEC USE ONLY

     

     4.  

     SOURCE OF FUNDS (SEE INSTRUCTIONS)

     

     WC

     5.  

     CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

     

     ☐

     6.  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

        7.   

     SOLE VOTING POWER

     

     0

        8.  

     SHARED VOTING POWER

     

     2,900,000

        9.  

     SOLE DISPOSITIVE POWER

     

     0

       10.  

     SHARED DISPOSITIVE POWER

     

     2,900,000

    11.   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     2,900,000

    12.  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    13.  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

     11.0% (1)

    14.  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     PN

     

    (1)

    Percent of class calculated based on 26,311,904 shares of Common Stock outstanding as of August 9, 2023, as reported by the Issuer in the Form 10-Q .

     

    - 4 -


    ITEM 1.

    Security and Issuer.

    The security to which this Schedule 13D relates is the Common Stock of HeartBeam, Inc., a Delaware corporation (the “Issuer”). The principal executive offices of the Issuer are located at 2118 Walsh Ave. Suite 210, Santa Clara, CA 95050.

     

    ITEM 2.

    Identity and Background.

    (a), (b), (c) and (f). This Schedule 13D is being filed jointly by Mark E. Strome, Strome Investment Management, L.P. (the “Manager”) and Strome Mezzanine Fund II, LP (the “Fund” and collectively with Mr. Strome and the Manager, the “Reporting Persons”), pursuant to the provisions of Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), as separate persons and not as members of a group. See Exhibit 99.1 to this Schedule 13D for their Joint Filing Agreement.

    Mark E. Strome

    The principal occupation of Mr. Strome is the Founder and Chief Executive Officer of Strome Group, Inc., the general partner of the Manager. The business address of Mr. Strome is c/o Strome Group, Inc., 1688 Meridian Avenue, Suite 727, Miami Beach, FL 33139. Mr. Strome is a citizen of the United States of America.

    Strome Investment Management, L.P.

    The Manager is a Delaware limited partnership whose principal business is to serve as general partner and investment manager of the Fund. The business address of the Manager is 1688 Meridian Avenue, Suite 727, Miami Beach, FL 33139.

    Strome Mezzanine Fund II, LP

    The Fund is a Delaware limited partnership whose principal business is to make investments. The business address of the Fund is 1688 Meridian Avenue, Suite 727, Miami Beach, FL 33139.

    (d) and (e). During the last five years, none of the Reporting Persons has been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and, as a result of such proceeding, was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws. During the last five years, none of the Reporting Persons has been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

     

    ITEM 3.

    Source and Amount of Funds or Other Consideration.

    The source of funds for the Common Stock reported herein by the Reporting Persons was the working capital of the Fund, Mark E. Strome Living Trust and Strome Dynasty, LLC.

     

    ITEM 4.

    Purpose of Transaction.

    The Reporting Persons acquired the Common Stock covered by this Schedule 13D for investment purposes, in the ordinary course of business.

    The Reporting Persons will routinely monitor a wide variety of investment considerations, including, without limitation, current and anticipated future trading prices for the Common Stock, the Issuer’s operations, assets, prospects, business development, markets and capitalization, the Issuer’s management and personnel, Issuer-related competitive and strategic matters, general economic, financial market and industry conditions, as well as other investment considerations. The Reporting Persons expect to discuss their investment in the Issuer and the foregoing investment considerations with the Issuer’s Board of Directors (“Board”), management, other investors, industry analysts and others. These considerations, these discussions and other factors may result in the Reporting Persons’

     

    - 5 -


    consideration of various alternatives with respect to their investment, including possible changes in the present Board and/or management of the Issuer or other alternatives to increase stockholder value. The Reporting Persons may also enter into confidentiality or similar agreements with the Issuer and, subject to such an agreement or otherwise, exchange information with the Issuer. In addition, the Reporting Persons may acquire additional Issuer securities in the public markets, in privately negotiated transactions or otherwise or may determine to sell, trade or otherwise dispose of all or some holdings in the Issuer in the public markets, in privately negotiated transactions or otherwise, or take any other lawful action they deem to be in their best interests.

    Except as set forth in this Item 4 and Item 6 below, no Reporting Person has any present plans or proposals that relate to or would result in: (a) the acquisition by any person of additional securities of the Issuer, or the disposition of securities of the Issuer; (b) an extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries; (c) a sale or transfer of a material amount of assets of the Issuer or of any of its subsidiaries; (d) any change in the present Board or management of the Issuer, including any plans or proposals to change the number or term of such directors or to fill any existing vacancies on such board; (e) any material change in the present capitalization or dividend policy of the Issuer; (f) any other material change in the Issuer’s business or corporate structure; (g) changes in the Issuer’s charter, by-laws or instruments corresponding thereto or other actions that may impede the acquisition of control of the Issuer by any person; (h) causing a class of securities of the Issuer to be delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association; (i) a class of equity securities of the Issuer becoming eligible for termination of registration pursuant to Section 12(g)(4) of the Exchange Act; or (j) any action similar to any of those enumerated in subparagraphs (a)-(i) above. There is no assurance that the Reporting Persons will develop any plans or proposals with respect to any of these matters. However, the Reporting Persons reserve the right to formulate plans or proposals which would relate to or result in the transactions described in subparagraphs (a) through (j) of this Item 4.

     

    ITEM 5.

    Interest in Securities of the Issuer.

    (a) The aggregate amount of Common Stock that may be deemed beneficially owned by the Reporting Persons is comprised of 3,150,000 shares of Common Stock held by the Redmile Funds. Redmile is the investment manager to the Redmile Funds and, in such capacity, exercises voting and investment power over all of the shares held by the Redmile Funds and may be deemed to be the beneficial owner of these shares. Mark E. Strome serves as the managing member of Redmile and also may be deemed to be the beneficial owner of these shares. Redmile and Mr. Strome each disclaims beneficial ownership of these shares, except to the extent of its or his pecuniary interest in such shares, if any.

    For purposes of this Schedule 13D, the percent of class was calculated based on 26,311,904 shares of Common Stock outstanding as of August 9, 2023, as reported by the Issuer in the Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2023 filed with the SEC on August 10, 2023.

    (b) Mark E. Strome:

    (1) Sole Voting Power: 0

    (2) Shared Voting Power: 3,150,000

    (3) Sole Dispositive Power: 0

    (4) Shared Dispositive Power: 3,150,000

    Strome Investment Management, L.P.:

    (1) Sole Voting Power: 0

    (2) Shared Voting Power: 2,900,000

    (3) Sole Dispositive Power: 0

    (4) Shared Dispositive Power: 2,900,000

     

    - 6 -


    Strome Mezzanine Fund II, LP:

    (1) Sole Voting Power: 0

    (2) Shared Voting Power: 2,900,000

    (3) Sole Dispositive Power: 0

    (4) Shared Dispositive Power: 2,900,000

    (c) No transactions in the Company’s securities have been effected by the Reporting Persons during the past sixty days.

    (d) Not applicable.

    (e) Not applicable.

     

    ITEM 6.

    Contracts, Arrangements, Understandings or Relationship with Respect to the Securities of the Issuer.

    On June 5, 2023, the Issuer’s Board appointed Mark E. Strome to serve as a director until the Issuer’s 2024 Annual Meeting of Stockholders and until his successor has been duly elected and qualified. In connection with Mr. Strome’s appointment to the Issuer’s Board, Mr. Strome and the Issuer entered into an indemnification in the same form as the Issuer’s standard form of indemnification agreement with its other directors.

    As a non-employee director, Mr. Strome is entitled to annual cash and equity compensation pursuant to the Issuer’s Outside Director Compensation Plan (the “Plan”). Pursuant to the Plan, Mr. Strome is entitled to receive an annual base cash retainer of $40,000 to be paid monthly. If Mr. Strome serves on any committees of the Issuer’s Board, he will be entitled to receive additional cash compensation. Under the Plan, non-employee directors receive $10,000 annually for serving on the audit committee ($25,000 annually for the chairman), $10,000 annually for serving on the compensation committee ($15,000 annually for the chairman), and $10,000 annually for serving on the nominating and corporate governance committee ($15,000 annually for the chairman).

    Pursuant to the Plan, Mr. Strome will also be entitled to receive restricted stock unit award on the date of each annual stockholder meeting of the Issuer, which restricted stock units will vest in full on the date of the following annual stockholder meeting of the Issuer. The dollars convert to shares based on the FMV at the date of grant.

    Except as described above, no contracts, arrangements, understandings, or relationships (legal or otherwise) exist between any Reporting Person and any person with respect to any securities of the Issuer, including, but not limited to, transfer or voting of any of the securities, finder’s fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, divisions of profits or loss, or the giving or withholding of proxies. Except as described above, none of the Reporting Persons is a party to any arrangement whereby securities of the Issuer are pledged or are otherwise subject to a contingency the occurrence of which would give another person voting power or investment power over such securities.

     

    - 7 -


    ITEM 7.

    Material to Be Filed as Exhibits.

     

    Exhibit
    Number

      

    Description

    Exhibit 99.1    Joint Filing Agreement, dated as of October 25, 2023, by and among Mark E. Strome, Strome Investment Management, L.P. and Strome Mezzanine Fund II, LP.

     

    - 8 -


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: October 25, 2023      

    /s/ Mark E. Strome

          MARK E. STROME
    Dated: October 25, 2023       STROME INVESTMENT MANAGEMENT, L.P.
         

    By: Strome Group, Inc.

    Its: General Partner

         

    /s/ Mark E. Strome

          Name: Mark E. Strome
          Title: Founder & CEO
    Dated: October 25, 2023       STROME MEZZANINE FUND II, LP
         

    By: Strome Investment Management, L.P.

    Its: General Partner

     

    By: Strome Group, Inc.

    Its: General Partner

         

    /s/ Mark E. Strome

          Name: Mark E. Strome
          Title: Founder & CEO

     

    Get the next $BEAT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BEAT

    DatePrice TargetRatingAnalyst
    12/20/2021$9.00Speculative Buy
    Benchmark
    More analyst ratings

    $BEAT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Benchmark initiated coverage on BioTelemetry with a new price target

      Benchmark initiated coverage of BioTelemetry with a rating of Speculative Buy and set a new price target of $9.00

      12/20/21 7:19:06 AM ET
      $BEAT
      Medical/Dental Instruments
      Health Care

    $BEAT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • HeartBeam Announces Two New U.S. Patents, Powering Forward Its Robust Patent Portfolio

      First patent significantly advances intellectual property for HeartBeam's credit card-sized ECG device, bolstering both the defensive and offensive moat around the company's core technology Second patent expands the use of risk-based diagnostic algorithms into HeartBeam's product portfolio around wearable devices HeartBeam now has 20 issued patents worldwide, cementing Company's leadership in cardiac monitoring innovation HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today announced the addition of two new U.S. patents, reinforcing its core intellectual property position and enabling futur

      5/6/25 7:00:00 AM ET
      $BEAT
      Medical/Dental Instruments
      Health Care
    • HeartBeam Appoints CEO Robert Eno to Board of Directors to Support U.S. Commercialization and Growth

      Board expansion reflects Company's commitment to leadership and innovation in remote cardiac monitoring HeartBeam, Inc., (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today announced the appointment of Chief Executive Officer, Robert Eno, to its Board of Directors. As the Company continues to make significant advancements towards commercial readiness, the Board elected to expand from eight to nine members to accommodate this addition. Mr. Eno joined HeartBeam as President in January 2023 and was appointed CEO in October 2024. With over 30 years of experience in the medical technology industry, he has a proven

      5/5/25 7:00:00 AM ET
      $BEAT
      Medical/Dental Instruments
      Health Care
    • HeartBeam to Host First Quarter 2025 Results Conference Call on Tuesday, May 13, 2025 at 4:30 p.m. Eastern Time

      HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, will hold a conference call on Tuesday, May 13, 2025 at 4:30 p.m. Eastern time to discuss its results for the first quarter ended March 31, 2025, and will be providing updates on regulatory initiatives, commercial-readiness activities and anticipated milestones. A press release detailing these results will be issued prior to the call. HeartBeam CEO Robert Eno and CFO Timothy Cruickshank will host the conference call, followed by a question-and-answer period. The conference call will be accompanied by a presentation, which can be viewed during the web

      5/1/25 8:31:00 AM ET
      $BEAT
      Medical/Dental Instruments
      Health Care

    $BEAT
    Leadership Updates

    Live Leadership Updates

    See more
    • HeartBeam Appoints CEO Robert Eno to Board of Directors to Support U.S. Commercialization and Growth

      Board expansion reflects Company's commitment to leadership and innovation in remote cardiac monitoring HeartBeam, Inc., (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today announced the appointment of Chief Executive Officer, Robert Eno, to its Board of Directors. As the Company continues to make significant advancements towards commercial readiness, the Board elected to expand from eight to nine members to accommodate this addition. Mr. Eno joined HeartBeam as President in January 2023 and was appointed CEO in October 2024. With over 30 years of experience in the medical technology industry, he has a proven

      5/5/25 7:00:00 AM ET
      $BEAT
      Medical/Dental Instruments
      Health Care
    • HeartBeam Announces FDA Clearance for At-Home, High-Fidelity Heart Monitoring Technology

      First cable-free, ambulatory ECG that captures the heart's electrical signals from three distinct directions for high-fidelity data collection and advanced diagnostics Patients can have the credit card-sized device with them at all times, ready to record an ECG whenever they feel symptoms and reduce delays in care Company to initiate Early Access Program to gain important patient and physician feedback on the use of the system in preparation for commercial launch HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced that the US Food and Drug Administration (FDA) has granted 510(k) cl

      12/16/24 8:31:00 AM ET
      $BEAT
      Medical/Dental Instruments
      Health Care
    • HeartBeam Appoints Robert Eno as Chief Executive Officer in Preparation for US Commercialization

      Industry leader brings extensive experience in developing go-to-market strategies for breakthrough products and delivering growth Founder and current CEO Branislav Vajdic named President to focus on advancing the Company's groundbreaking vector-based technology for heart health, including AI applications HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful insights wherever the patient is, announced that Robert Eno has been appointed Chief Executive Officer (CEO), effective Monday, October 21, 2024. The seasoned MedTech executive joined HeartBeam as President in January 2023 and will lead as the Company continues to work

      10/17/24 8:31:00 AM ET
      $BEAT
      Medical/Dental Instruments
      Health Care

    $BEAT
    SEC Filings

    See more
    • Heartbeam Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - HeartBeam, Inc. (0001779372) (Filer)

      5/5/25 10:00:43 AM ET
      $BEAT
      Medical/Dental Instruments
      Health Care
    • Heartbeam Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits

      8-K - HeartBeam, Inc. (0001779372) (Filer)

      4/25/25 3:38:24 PM ET
      $BEAT
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-K filed by Heartbeam Inc.

      10-K - HeartBeam, Inc. (0001779372) (Filer)

      3/13/25 4:20:54 PM ET
      $BEAT
      Medical/Dental Instruments
      Health Care

    $BEAT
    Financials

    Live finance-specific insights

    See more
    • HeartBeam to Host First Quarter 2025 Results Conference Call on Tuesday, May 13, 2025 at 4:30 p.m. Eastern Time

      HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, will hold a conference call on Tuesday, May 13, 2025 at 4:30 p.m. Eastern time to discuss its results for the first quarter ended March 31, 2025, and will be providing updates on regulatory initiatives, commercial-readiness activities and anticipated milestones. A press release detailing these results will be issued prior to the call. HeartBeam CEO Robert Eno and CFO Timothy Cruickshank will host the conference call, followed by a question-and-answer period. The conference call will be accompanied by a presentation, which can be viewed during the web

      5/1/25 8:31:00 AM ET
      $BEAT
      Medical/Dental Instruments
      Health Care
    • HeartBeam to Host Fourth Quarter Full Year 2024 Results Conference Call on Thursday, March 13, 2025 at 4:30 p.m. Eastern Time

      HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, will hold a conference call on Thursday, March 13, 2025 at 4:30 p.m. Eastern time to discuss its results for the fourth quarter and full year ended December 31, 2024, and will be providing updates on regulatory initiatives, commercial-readiness activities and anticipated milestones. A press release detailing these results will be issued prior to the call. HeartBeam CEO Robert Eno and CFO Timothy Cruickshank will host the conference call, followed by a question-and-answer period. The conference call will be accompanied by a presentation, which can be

      2/27/25 8:31:00 AM ET
      $BEAT
      Medical/Dental Instruments
      Health Care
    • HeartBeam Reports Third Quarter 2024 Results

      Continued Clinical and Regulatory Progress on the HeartBeam System Key Appointments to Management Team Completed as Part of Planned Evolution in Preparation for US Commercialization Strengthening Clinical Evidence Base, with Two Additional Studies to be Presented at the American Heart Association Conference in November 2024 Management to Host Webcast and Conference Call Today at 4:30 p.m. ET HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, has reported its financial and operational results for the third quarter ended September 30, 2024. Third Quarter & Subsequent 2024 Operational Highlights

      11/7/24 4:05:00 PM ET
      $BEAT
      Medical/Dental Instruments
      Health Care

    $BEAT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by Heartbeam Inc.

      SC 13D - HeartBeam, Inc. (0001779372) (Subject)

      10/25/23 4:01:55 PM ET
      $BEAT
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13D filed by Heartbeam Inc.

      SC 13D - HeartBeam, Inc. (0001779372) (Subject)

      8/28/23 4:26:34 PM ET
      $BEAT
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13D filed by Heartbeam Inc.

      SC 13D - HeartBeam, Inc. (0001779372) (Subject)

      6/2/23 2:36:13 PM ET
      $BEAT
      Medical/Dental Instruments
      Health Care

    $BEAT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Financial Officer Cruickshank Tim

      4 - HeartBeam, Inc. (0001779372) (Issuer)

      5/1/25 11:06:06 AM ET
      $BEAT
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Chief Executive Officer Eno Robert Paul

      4 - HeartBeam, Inc. (0001779372) (Issuer)

      5/1/25 11:05:46 AM ET
      $BEAT
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Chief Technology Officer Persen Kenneth Harry

      4 - HeartBeam, Inc. (0001779372) (Issuer)

      5/1/25 11:03:46 AM ET
      $BEAT
      Medical/Dental Instruments
      Health Care

    $BEAT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Ferrari Richard bought $50,000 worth of shares (29,412 units at $1.70), increasing direct ownership by 20% to 179,136 units (SEC Form 4)

      4 - HeartBeam, Inc. (0001779372) (Issuer)

      2/21/25 8:00:22 PM ET
      $BEAT
      Medical/Dental Instruments
      Health Care
    • CFO Cruickshank Tim bought $30,000 worth of shares (17,647 units at $1.70) (SEC Form 4)

      4 - HeartBeam, Inc. (0001779372) (Issuer)

      2/21/25 7:55:14 PM ET
      $BEAT
      Medical/Dental Instruments
      Health Care